4-(dimethylamino)pyrimidine-2-carbonitrile | 500160-46-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-(dimethylamino)pyrimidine-2-carbonitrile
• CAS: 500160-46-3
• 化学式: C₇H₈N₄
• 分子量: 148.167
• InChiKey: BUQRTVMMUMPDMR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  52.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(dimethylamino)pyrimidine-2-carbonitrile 在 ammonium hydroxide 、 氢气 作用下， 以 甲醇 为溶剂， 反应 1.0h， 生成 2-(aminomethyl)-N,N-dimethylpyrimidin-4-amine
  参考文献：
  名称：

  WO2020035052A5

  摘要：

  公开号：

  WO2020035052A5
• 作为产物：
  描述：

  4-溴嘧啶-2-甲腈 、 二甲胺 以 四氢呋喃 为溶剂， 反应 6.0h， 以88.7%的产率得到4-(dimethylamino)pyrimidine-2-carbonitrile
  参考文献：
  名称：

  WO2020035052A5

  摘要：

  公开号：

  WO2020035052A5

文献信息

• Pyrazine compounds and uses thereof
  申请人：Dizal (Jiangsu) Pharmaceutical Co., Ltd.

  公开号：US10898481B2

  公开（公告）日：2021-01-26

  The present disclosure novel pyrazine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.

  本公开涉及以腺苷受体（特别是 A1 和 A2，尤其是 A2a）为靶点的新型吡嗪化合物。本公开还涉及包含一种或多种化合物作为活性成分的药物组合物，以及这些化合物在治疗腺苷受体（AR）相关疾病中的用途，例如癌症，如 NSCLC、RCC、前列腺癌和乳腺癌。
• High-Efficacy 5-HT_1A Agonists for Antidepressant Treatment:  A Renewed Opportunity
  作者：Jean Louis Maurel、Jean-Marie Autin、Philippe Funes、Adrian Newman-Tancredi、Francis Colpaert、Bernard Vacher

  DOI：10.1021/jm070714l

  日期：2007.10.1

  We report the discovery of novel 5-HT1A receptor agonists and describe the process that led to the antidepressant candidate 9 (F 15599). 9 has nanomolar affinity for 5-HT1A binding sites and is over 1000-fold selective with respect to the other 5-HT1 receptor subtypes, 5-HT2-7 receptor families, and also numerous GPCRs, transporters, ion channels, and enzymes. In a cellular model of signal transduction, 9 activates h5-HT1A receptors with an efficacy superior to that of the prototypical 5-HT1A agonist (+/-)-8-OH-DPAT and comparators undergoing clinical trials. After acute oral administration in rats, 9 totally reverses immobility in the forced swimming test and produces behaviors characteristic of 5-HT1A receptor activation. However, these effects occurred at widely separated doses, suggesting that 9 discriminates between distinct populations of 5-HT1A receptors. While the clinical relevance of these observations is still unknown, this opens new perspectives for the treatment of depressive disorders.
• PYRAZINE COMPOUNDS AND USES THEREOF
  申请人：Dizal (Jiangsu) Pharmaceutical Co., Ltd.

  公开号：US20200330458A1

  公开（公告）日：2020-10-22

  The present disclosure novel pyrazine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.
• [EN] POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP<br/>[FR] POLYMÈRES FONCTIONNALISÉS PAR DES COMPOSÉS NITRILE CONTENANT UN GROUPE AMINO PROTÉGÉ
  申请人：BRIDGESTONE CORP

  公开号：WO2011091346A2

  公开（公告）日：2011-07-28

  A method for preparing a functionalized polymer, the method comprising the steps of: (i) polymerizing monomer with an anionic initiator to form a reactive polymer; and (ii) reacting the reactive polymer with a nitrile compound containing a protected amino group, where the protected amino group is directly attached to a moiety selected from the group consisting of acyclic moieties, heterocyclic moieties, and non-aromatic cyclic moieties.
• WO2020035052A5
  申请人：——

  公开号：WO2020035052A5

  公开（公告）日：2022-08-04